Entering text into the input field will update the search result below

Tonix Pharma gets FDA response ahead of studies for live virus COVID-19 shot

Close-up of bottles of COVID-19 vaccine
peterschreiber.media/iStock via Getty Images

  • Tonix Pharmaceuticals (NASDAQ:TNXP) has added ~5.3% in the pre-market after the company said it received an official written response from the FDA following a Type B pre-Investigational New Drug (IND) meeting for potential COVID-19

Recommended For You

About TNXP Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TNXP--
Tonix Pharmaceuticals Holding Corp.